Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Healthtrust
McKesson
AstraZeneca
McKinsey
Moodys
Fish and Richardson
Daiichi Sankyo
Dow
UBS

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,199,908

« Back to Dashboard

Summary for Patent: 9,199,908
Title:Compounds and methods for delivery of prostacyclin analogs
Abstract: This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
Inventor(s): Phares; Ken (Chapel Hill, NC), Mottola; David (Cary, NC), Jeffs; Roger (Chapel Hill, NC), Wade; Michael (Chapel Hill, NC)
Assignee: United Therapeutics Corporation (Silver Spring, MD)
Application Number:14/490,014
Patent Claim Types:
see list of patent claims
Use; Formulation;

Drugs Protected by US Patent 9,199,908

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-001 May 21, 2002 RX Yes No ➤ Subscribe ➤ Subscribe ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION OR 0.9% SODIUM CHLORIDEINJECTION PRIOR TO ADMINISTRATION ➤ Subscribe
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-002 May 21, 2002 RX Yes No ➤ Subscribe ➤ Subscribe ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION OR 0.9% SODIUM CHLORIDEINJECTION PRIOR TO ADMINISTRATION ➤ Subscribe
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-003 May 21, 2002 RX Yes No ➤ Subscribe ➤ Subscribe ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION OR 0.9% SODIUM CHLORIDEINJECTION PRIOR TO ADMINISTRATION ➤ Subscribe
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-004 May 21, 2002 RX Yes Yes ➤ Subscribe ➤ Subscribe ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION OR 0.9% SODIUM CHLORIDEINJECTION PRIOR TO ADMINISTRATION ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,199,908

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,252,839 Compounds and methods for delivery of prostacyclin analogs ➤ Subscribe
9,624,156 Compounds and methods for delivery of prostacyclin analogs ➤ Subscribe
7,384,978 Compounds and methods for delivery of prostacyclin analogs ➤ Subscribe
9,050,311 Compounds and methods for delivery of prostacyclin analogs ➤ Subscribe
7,417,070 Compounds and methods for delivery of prostacyclin analogs ➤ Subscribe
8,410,169 Compounds and methods for delivery of prostacyclin analogs ➤ Subscribe
8,232,316 Compounds and methods for delivery of prostacyclin analogs ➤ Subscribe
7,544,713 Compounds and methods for delivery of prostacyclin analogs ➤ Subscribe
9,422,223 Compounds and methods for delivery of prostacyclin analogs ➤ Subscribe
8,536,363 Compounds and methods for delivery of prostacyclin analogs ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,199,908

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea 20060021862 ➤ Subscribe
Japan 2012162539 ➤ Subscribe
Japan 5043433 ➤ Subscribe
Japan 2007501281 ➤ Subscribe
Spain 2622471 ➤ Subscribe
European Patent Office 2792353 ➤ Subscribe
European Patent Office 1628654 ➤ Subscribe
China 102697790 ➤ Subscribe
China 101780092 ➤ Subscribe
China 101265226 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Cerilliant
Dow
Teva
US Army
Harvard Business School
Queensland Health
Novartis
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot